Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]
Topic prioritisation
Following the written consultation on the draft remit and scope and discussions at the scoping workshop, NICE compiled a summary of its findings into a report that was discussed at the Topic Selection Oversight Panel (TSOP) in November 2020. The report included advice and recommendations to aid the decision-making process.
TSOP concluded that an appraisal of remimazolam for sedation for people having diagnostic or therapeutic procedures was not appropriate. This means the technology in this indication will not be appraised by NICE.